GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Ardent Health ARDT · USD

Health Care · US listing · 🇺🇸 United States

Compare

17.97

+3.87%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$6.32bn

FY2015FY2025

Net income

$135.8m

FY2015FY2025

Free cash flow

$258.6m

FY2015FY2025

Shareholders' equity

$1.69bn

FY2015FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2018FY2017FY2016FY2015
Revenue$6.32bn$5.97bn$5.41bn$5.13bn$4.87bn$4.16bn$3.00bn$2.11bn$2.03bn
Research and development—————$15.7m$19.9m——
Operating income$325.6m$405.8m$229.5m$299.1m$436.6m$149.8m$121.8m$84.8m$126.0m
Net income$135.8m$210.3m$50.3m$188.9m$154.3m−$143.0m−$35.6m$14.6m−$46.4m
Diluted earnings per share0.961.580.351.501.08-0.30-0.250.10-0.61

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2018FY2017FY2016FY2015
Total assets$5.29bn$4.96bn$5.10bn$4.86bn—$2.75bn$2.37bn$1.09bn—
Cash and short-term investments$709.6m$556.8m$437.6m$456.1m—$59.7m$72.0m$92.6m—
Total liabilities$3.61bn$3.43bn$4.02bn$3.81bn—$2.03bn$1.61bn$689.4m—
Debt$1.10bn$1.10bn$1.19bn$1.18bn—$9.0m$16.9m$7.7m—
Shareholders' equity$1.69bn$1.13bn$670.9m$639.0m—$331.6m$377.7m$266.5m—
Shares outstanding141m133m142m126m143m474m141m141m76m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2018FY2017FY2016FY2015
Cash from operations$470.5m$315.0m$221.7m−$38.4m$146.9m$159.6m$119.5m$85.8m$119.8m
Capital spending−$211.9m−$187.5m−$137.4m−$151.1m−$139.0m−$160.7m−$121.5m−$80.5m−$80.5m
Free cash flow$258.6m$127.5m$84.3m−$189.5m$7.9m−$1.1m−$2.1m$5.3m$39.3m
Dividends paid———−$174.8m−$62.1m———−$558.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.62bn$1.60bn$1.61bn$1.58bn$1.65bn$1.50bn$1.61bn$1.45bn
Operating income$43.2m$80.9m$117.1m$254.3m$137.3m$88.4m$336.8m$70.4m
Net income$16.9m$39.9m$45.0m−$23.5m$73.0m$41.4m$114.2m$26.3m
Diluted earnings per share0.120.280.32-0.170.520.290.860.20
Cash from operations$196.0m−$60.0m$221.0m$151.0m$117.0m−$24.0m$119.0m$92.0m
Capital spending−$38.0m−$28.0m−$83.0m−$58.0m−$46.0m−$22.0m−$81.0m−$43.0m
Free cash flow$158.0m−$88.0m$138.0m$93.0m$71.0m−$46.0m$38.0m$49.0m
Total assets$5.28bn$5.25bn$5.29bn$5.15bn$5.03bn$4.91bn$4.96bn$4.80bn
Cash and short-term investments$724.5m$609.7m$709.6m$609.4m$540.6m$495.0m$556.8m$563.1m
Debt$28.6m$1.11bn$1.10bn$1.11bn$1.11bn$1.11bn$1.14bn$1.10bn
Shareholders' equity$1.35bn$1.73bn$1.69bn$1.24bn$1.25bn$1.18bn$1.13bn$1.01bn

Financial ratios

Data as of 3 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2018FY2017
Operating margin5.4%7.2%3.9%7.7%8.0%2.5%—
Net margin2.1%3.5%0.9%3.7%3.2%-3.4%—
Return on equity8.1%18.6%7.5%29.6%—-43.1%-9.4%
Return on assets2.6%4.2%1.0%3.9%—-5.2%-1.5%
Free cash flow yield41.1%32.3%21.5%7.6%—5.8%14.6%
Revenue growth6.0%10.3%5.5%5.3%17.0%38.6%—
Earnings growth-35.4%318.2%-73.4%22.5%-207.9%301.2%—
Current ratio1.97x1.94x1.63x1.74x—1.38x1.45x
Debt to equity0.65x1.01x1.83x1.91x—0.03x0.04x
Equity ratio31.9%22.8%13.1%13.1%—12.1%15.9%
Interest coverage6.19x6.54x3.20x4.80x4.15x0.94x—
R&D as a share of sales—————0.4%0.7%
Buybacks as a share of market value-6.6%6.6%-12.8%73.4%—-236.1%-85.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue7.2%8.7%—
Operating income2.9%16.8%—
Net income-10.4%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings9.210.8
Price to sales0.20.4

Market value over time

31 Jul 2024 to 2 Nov 2026, in USD

$2.55bn$1.68bn

Share price return

Finished calendar years

20252024
Return-45%1%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.